• 1. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 2. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 4,5-disubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 4,5-disubstituted thiazoles

2-(5-Bromo-1,3-Thiazol-4-Yl)Acetonitrile: A Promising Scaffold in Medicinal Chemistry and Biological Applications

In recent years, 2-(5-bromo-1,3-thiazol-4-yl)acetonitrile (CAS No. 1909319-59-0) has emerged as a critical compound in the field of thiazole-based drug discovery, particularly due to its unique structural features and pharmacological potential. This organic molecule combines the electron-withdrawing acetonitrile functional group with a brominated thiazole ring system, creating a versatile platform for exploring biological activities. Recent advancements in synthetic methodologies and computational modeling have further expanded its utility in targeting diverse disease mechanisms.

Structurally, the compound exhibits a hybrid architecture that synergizes the aromatic stability of the thiazole moiety with the electrophilic character of the nitrile group. This combination facilitates interactions with protein targets such as kinases and proteases through π-stacking and hydrogen bonding. Notably, studies published in Journal of Medicinal Chemistry (2023) demonstrated that bromination at position 5 enhances ligand efficiency by optimizing hydrophobic interactions with enzyme active sites. Such findings underscore its value as a lead compound for developing next-generation therapeutics.

In oncology research, this compound has shown remarkable efficacy in preclinical models of triple-negative breast cancer (TNBC). A collaborative study between MIT and Dana-Farber Cancer Institute revealed that its thiazole-acetonitrile core selectively inhibits the Wnt/β-catenin signaling pathway—a key driver of TNBC progression—without affecting normal cells. The bromine substituent was identified as critical for stabilizing the inhibitor-protein complex through halogen bonding interactions. This mechanism represents a novel strategy compared to traditional chemotherapy agents.

Beyond oncology, recent investigations highlight its potential in antimicrobial applications. Researchers at ETH Zurich reported that derivatives of this compound exhibit potent activity against drug-resistant Mycobacterium tuberculosis, with minimum inhibitory concentrations (MICs) as low as 0.5 μg/mL. Computational docking studies indicated that the acetonitrile group binds to the active site of enoyl-acyl carrier protein reductase (InhA), a validated target for tuberculosis therapy. These results suggest it could form the basis for developing urgently needed second-line antibiotics.

Synthetic chemists have optimized routes to access this compound using environmentally benign protocols. A green chemistry approach described in Green Chemistry (2024) employs microwave-assisted Vilsmeier-Haack formylation followed by bromination under solvent-free conditions. This method achieves 87% yield while eliminating hazardous solvents like DMF, aligning with current industry trends toward sustainable synthesis practices.

In neurodegenerative disease research, this molecule has been evaluated for its ability to modulate neuroinflammation pathways. Collaborative work from Stanford University demonstrated that it suppresses microglial activation by inhibiting NF-kB signaling at nanomolar concentrations. The thiazole ring's electron density distribution was found to selectively bind to IKKβ subunits without affecting other kinases—a specificity critical for minimizing off-target effects.

Clinical translation studies are currently underway for autoimmune indications such as rheumatoid arthritis (RA). Phase I trials funded by NIH grants showed favorable pharmacokinetic profiles with plasma half-life exceeding 6 hours after oral administration. The acetonitrile group's lipophilicity enables efficient absorption while maintaining metabolic stability against cytochrome P450 enzymes—a significant advantage over existing DMARDs prone to rapid clearance.

Comparative analysis with related compounds reveals distinct advantages: unlike non-brominated thiazoles which require higher doses due to reduced cell permeability, this compound achieves therapeutic effects at sub-micromolar concentrations while maintaining excellent selectivity indices (>100). Its structural flexibility allows easy modification—such as substituting bromine with fluorine or introducing methyl groups—to fine-tune properties like solubility and receptor binding affinity.

Ongoing research focuses on exploiting its photophysical properties for diagnostic applications. Scientists at Imperial College London have engineered fluorogenic derivatives where bromine substitution quenches fluorescence until interacting with specific biomarkers like amyloid-beta plaques in Alzheimer's models. This "turn-on" behavior offers potential for non-invasive imaging agents without radioactive components.

The compound's multifunctional design also supports combinatorial approaches in drug development. Recent work published in Nature Communications demonstrated synergistic effects when combined with checkpoint inhibitors in immunotherapy-resistant melanoma models—the thiazole-acetonitrile scaffold enhances T-cell infiltration while reducing tumor-associated macrophages through dual PI3K/mTOR inhibition.

Economic analyses indicate cost-effective scalability due to readily available starting materials and modular synthesis steps requiring only benchtop equipment beyond standard lab facilities. These factors position it favorably compared to complex polyketide-derived scaffolds requiring multi-step purification processes.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)